Basket | Login | Register


CREAD2 study

Clinical Trials Watch

Click here to download an accessible easy read version of this document.

Studies Information

Scientific title

“A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease”

Study sponsor

Hoffmann- La Roche


Prodromal to mild Alzheimer’s disease                 

Information about the drug that will be tested in the study

Name of drug



  • The drug will be administered via an intravenous infusion (an injection into the vein) once every four weeks
  • The infusion lasts around 60 minutes

Is the drug already on the market for another medical condition?


Will all participants receive the same drug?

Participants will be selected at random to either receive one of the following options:

  • An intravenous infusion of Crenezumab


  • An intravenous infusion of placebo (also called a dummy treatment which is an inactive substance identical in appearance to the drug being tested).

Neither the participant nor his/her doctor will know if the person is receiving the investigational drug or the placebo.

Information about participating in the trial

What are the researchers trying to find out?

The researchers aim to evaluate the efficacy of Crenezumab in people with prodromal or mild Alzheimer’s disease.

How long will the treatment last?

  • Participants will receive an infusion every 4 weeks for 100 weeks (approximately 2 years).
  • Each infusion will last approximately 60 minutes

What will your involvement entail?

  • Participants will have to undergo a PET scan or CSF examination (spinal tap) to see if they have amyloid pathology in their brain.
  • During the study, participants will be asked to complete different tests that will assess their memory, functioning, behaviour, quality of life and medical assessments for overall health.

Further information on the procedures, tests and number of visits can be obtained from the study team.

Who can participate in the study?

Who can participate in the study?

To take part in the study, the person must:

  • Have a study partner / informant who has a sufficient contact with the participant, is willing to accompany the participant to all study visits, provides the necessary information about the participant’s memory, behaviour and functioning, and is willing to sign the necessary consent forms.
  • Weight between 40 and 120 kg.
  • Be fluent in the language of the tests used at the study site
  • Have adequate sight and hearing with glasses or hearing aid if required.
  • Have evidence of abnormal accumulation of amyloid in their brain (as per results of CSF examination (spinal tap) or of PET scan).
  • Have an impairment in their memory at screening visit.
  • Have a score between 22-30 points in the MMSE test (a test about your memory) and between 0.5 and 1.0 in the Clinical Dementia Rating-Global Score (CDR-GS). This would suggest that the person has an impairment in their memory that is still at a mild stage.
  • Meet the clinical criteria for probable Alzheimer’s dementia or prodromal Alzheimer’s disease of the National Institute on Aging/Alzheimer's Association (NIAAA).
  • If the person is taking an approved anti-dementia medication (i.e. donepezil, rivastigmine, galantamine or memantine) the dosing regimen must have been stable for at least 3 month prior to the screening visit.

Who cannot participate in the study?

People cannot take part in the study if they have or have experienced:

  • Any evidence of a condition other than Alzheimer’s disease that may affect cognition (e.g. other type of dementia, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological involvement).
  • History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
  • At risk of suicide in the opinion of the investigator
  • Presence of significant cerebral vascular pathology as assessed by MRI (Magnetic resonance imaging) central reader
  • Unstable or clinically significant cardiovascular, kidney or liver disease or uncontrolled hypertension
  • Poor peripheral venous access (this is when it is difficult to introduce a needle in the veins of the arm or hand of the person).
  • History of cancer except if considered to be cured or if not being actively treated with anti-cancer therapy or radiotherapy
  • Known history of severe allergy or hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.

The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study

Where and when will the study be conducted?

European countries involved in the trial

  • Belgium
  • Denmark
  • Estonia
  • France
  • Germany
  • Israel
  • Italy 
  • Norway
  • Poland
  • Portugal
  • Russian Federation
  • Serbia
  • Spain
  • Sweden
  • Turkey
  • United Kingdom

Estimated start date of recruitment

February 2017

Information for your doctor

EudraCT Number

2016-003288-20 identifier


Link to full text

Contact information


The information contained in this document is based on information available on public registries (e.g. website) on March 2018.

The pharmaceutical company running these trials (Hoffmann-La Roche) has reviewed this document.

This document has been reviewed by a member of the European Working Group of People with Dementia.






Last Updated: Monday 19 March 2018